» Articles » PMID: 10930454

Involvement of an SHP-2-Rho Small G Protein Pathway in Hepatocyte Growth Factor/scatter Factor-induced Cell Scattering

Overview
Journal Mol Biol Cell
Date 2000 Aug 10
PMID 10930454
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocyte growth factor/scatter factor (HGF/SF) induces cell scattering through the tyrosine kinase-type HGF/SF receptor c-Met. We have previously shown that Rho small G protein (Rho) is involved in the HGF/SF-induced scattering of Madin-Darby canine kidney (MDCK) cells by regulating at least the assembly and disassembly of stress fibers and focal adhesions, but it remains unknown how c-Met regulates Rho activity. We have found here a novel signaling pathway of c-Met consisting of SHP-2-Rho that regulates the assembly and disassembly of stress fibers and focal adhesions in MDCK cells. SHP-2 is a protein-tyrosine phosphatase that contains src homology-2 domains. Expression of a dominant negative mutant of SHP-2 (SHP-2-C/S) markedly increased the formation of stress fibers and focal adhesions in MDCK cells and inhibited their scattering. C3, a Clostridium botulinum ADP-ribosyltransferase, and Y-27632, a specific inhibitor for ROCK, reversed the stimulatory effect of SHP-2-C/S on stress fiber formation and the inhibitory effect on cell scattering. Vav2 is a GDP/GTP exchange protein for Rho. Expression of a dominant negative mutant of Vav2 blocked the stimulatory effect of SHP-2-C/S on stress fiber formation. Conversely, expression of mutants of Vav2 that increased stress fiber formation inhibited HGF/SF-induced cell scattering. These results indicate that SHP-2 physiologically modulates the activity of Rho to form stress fibers and focal adhesions and thereby regulates HGF/SF-induced cell scattering. In addition, Vav2 may be involved in the SHP-2-Rho pathway.

Citing Articles

Protein tyrosine phosphatase 11 acts through RhoA/ROCK to regulate eosinophil accumulation in the allergic airway.

Xu C, Wu X, Lu M, Tang L, Yao H, Wang J FASEB J. 2019; 33(11):11706-11720.

PMID: 31361966 PMC: 6902720. DOI: 10.1096/fj.201900698R.


Epithelial polarization in 3D matrix requires DDR1 signaling to regulate actomyosin contractility.

Sogaard P, Ito N, Sato N, Fujita Y, Matter K, Itoh Y Life Sci Alliance. 2019; 2(1).

PMID: 30760555 PMC: 6374992. DOI: 10.26508/lsa.201800276.


Tyrosine dephosphorylated cortactin downregulates contractility at the epithelial zonula adherens through SRGAP1.

Liang X, Budnar S, Gupta S, Verma S, Han S, Hill M Nat Commun. 2017; 8(1):790.

PMID: 28983097 PMC: 5629210. DOI: 10.1038/s41467-017-00797-w.


Hepatocyte Growth Factor Isoforms in Tissue Repair, Cancer, and Fibrotic Remodeling.

Mungunsukh O, McCart E, Day R Biomedicines. 2017; 2(4):301-326.

PMID: 28548073 PMC: 5344272. DOI: 10.3390/biomedicines2040301.


Physiological Signaling and Structure of the HGF Receptor MET.

Baldanzi G, Graziani A Biomedicines. 2017; 3(1):1-31.

PMID: 28536396 PMC: 5344233. DOI: 10.3390/biomedicines3010001.


References
1.
Manes S, Mira E, Zhao Z, Lacalle R, Martinez-A C . Concerted activity of tyrosine phosphatase SHP-2 and focal adhesion kinase in regulation of cell motility. Mol Cell Biol. 1999; 19(4):3125-35. PMC: 84106. DOI: 10.1128/MCB.19.4.3125. View

2.
Noguchi T, Matozaki T, Fujioka Y, Yamao T, Tsuda M, Takada T . Characterization of a 115-kDa protein that binds to SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in Chinese hamster ovary cells. J Biol Chem. 1996; 271(44):27652-8. DOI: 10.1074/jbc.271.44.27652. View

3.
Qi J, Ito N, Claesson-Welsh L . Tyrosine phosphatase SHP-2 is involved in regulation of platelet-derived growth factor-induced migration. J Biol Chem. 1999; 274(20):14455-63. DOI: 10.1074/jbc.274.20.14455. View

4.
Ridley A, Allen W, Peppelenbosch M, Jones G . Rho family proteins and cell migration. Biochem Soc Symp. 1999; 65:111-23. View

5.
Kodama A, Takaishi K, Nakano K, Nishioka H, Takai Y . Involvement of Cdc42 small G protein in cell-cell adhesion, migration and morphology of MDCK cells. Oncogene. 1999; 18(27):3996-4006. DOI: 10.1038/sj.onc.1202773. View